He is currently executive director and CSO of Trinity Biotech Plc, (NASDAQ: TRIB) an Irish Diagnostics company and executive chairman of Biosensia Ltd., an Irish Point of Care Diagnostics Company. He is also an investor in and director of a number of early stage Diagnostic companies, including Enzolve Technologies Ltd. (Paediatric testing), Epona Biotech (Animal Haematology), Crescent Diagnostics Ltd., (Bone Health).
Previously Prof. Walsh was Executive Chairman of GenCell Biosystems Ltd., acquired by Becton Dickenson in 2014 and CEO of Stokes Bio Ltd., acquired by Life Technologies in 2010, non-executive director at PuriCore Plc. (LSE: PURI) and Managing Director of Cambridge Diagnostics Ltd. a wholly owned subsidiary of Alere Inc.
Prof. Walsh bring a wealth of commercial and industry expertise to the company.
He is also the European venture partner for SOSV a $200m international investment fund and is currently running a Synthetic Biology Accelerator Program, IndieBio, in Cork, focusing on entrepreneurs building technologies in or around the field of Synthetic biology.
Previously, Bill co-founded XING, a pioneering business social networking platform in 2003 and served as COO of Davnet a telecommunications carrier that went public in the late 90’s. Bill serves as a special diplomatic envoy for St Kitt’s and Nevis, with an emphasis on sustainable development and the environment. Author of three books, he is a regular speaker at many events and venues such as The London School of Economics, The World Economic Forum, The Globe Forum in Sweden, The House of Commons and TED.
Rappold also co-authored the chapter “Development and Validation of Small Molecule Analytes By Liquid Chromatography-Tandem Mass Spectrometry” in the 6th edition of the Tietz Textbook of Clinical Chemistry and Molecular Diagnostics (2016). This classic chemistry reference is considered the most current and authoritative guidance on selecting, performing, and evaluating the results of new and established laboratory tests.
In April 2015, he became a founder of Altan Pharma Ltd., which acquired the GES group of companies which operate out of Spain, for €87m.
Mr. O’Kelly serves on the boards of Youth Conservation Corps, Inc., and the Clara Abbott Foundation